Last reviewed · How we verify
Phase 1 Study Of SNX-5422 Mesylate In Adults With Refractory Solid Tumor Malignancies And Lymphomas
Hsp90 is a chemical in the body that is involved in promotion of cancer. SNX-5422 is an experimental drug that blocks Hsp90. It is being evaluated for safety and efficacy in patients with cancer.
Details
| Lead sponsor | Esanex Inc. |
|---|---|
| Phase | Phase 1 |
| Status | COMPLETED |
| Enrolment | 32 |
| Start date | 2008-03 |
| Completion | 2010-09 |
Conditions
- Solid Tumor Malignancy
- Lymphoid Malignancy (Lymphoma and CLL)
- Leukemia
- Lymphoma
Interventions
- SNX-5422 Mesylate Hsp90 inhibitor
Primary outcomes
- MTD, safety and toxicity — continuous
Countries
United States